FCMI
PACB icon

Foresite Capital Management III’s Pacific Biosciences PACB Stock Holding History

Foresite Capital Management III’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,135,000
Closed -$6.14M – 24
2018
Q3 		$6.14M Buy
+1,135,000
New +$4.87M 1.35% 17
2018
Q1 		– Sell
-447,520
Closed -$1.18M – 25
2017
Q4 		$1.18M Sell
447,520
-702,480
-61% -$2.46M 0.33% 17
2017
Q3 		$6.04M Sell
1,150,000
-100,000
-8% -$430K 1.66% 14
2017
Q2 		$4.45M Buy
+1,250,000
New +$5.04M 1.45% 15

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Foresite Capital Management III's PACB Position: Q4 2018 in Review

Foresite Capital Management III sold out of Pacific Biosciences (PACB) in Q4 2018, closing a stake of 1,135,000 shares — an estimated $6.14M sold.

Foresite Capital Management III first reported a position in PACB in Q2 2017 and held it in 4 quarters. The position peaked at $6.14M in Q3 2018. 155 funds tracked by Wall St. Rank hold PACB as of Q4 2018.

  • Foresite Capital Management III reported no remaining Pacific Biosciences position as of Q4 2018 after selling out during the quarter.
  • Foresite Capital Management III sold 1,135,000 Pacific Biosciences shares in Q4 2018, an estimated $6.14M.
  • Foresite Capital Management III first reported a position in Pacific Biosciences in Q2 2017 and held it in 4 quarters.
  • Foresite Capital Management III's Pacific Biosciences position peaked at $6.14M in Q3 2018.
  • 155 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2018.

Based on Foresite Capital Management III's 13F filing for Q4 2018, filed 13 Feb 2019.